Table 1 Baseline demographics and patient characteristics
| Baseline characteristic |
Patients (N = 20) |
|---|---|
| Age, years | 10.5 (5–16) |
| Age group, n (%) | |
| 4–8 years | 8 (40) |
| 9–12 years | 7 (35) |
| 13–17 years | 5 (25) |
| Weight, kg | 37.9 (15.4–68.3) |
| Female, n (%) | 15 (75) |
| Race: Japanese, n (%) | 20 (100) |
| Disease duration, years | 0.75 (0.2–11.9) |
| Number of active joints | 6.0 (2.0–19.0) |
| Number of joints with LOM | 4.0 (2.0–10.0) |
| Parent Global Assessment, VAS 100 mm | 37.5 (0–94.0) |
| Physician Global Assessment, VAS 100 mm | 37.0 (10–80.0) |
| CHAQ-DI | 0.63 (0–2.88) |
| CRP, mg/dL | 0.58 (0.02–2.67) |
| JADAS27-CRP | 12.0 (4.2–26.4) |
| JIA disease subtype at study entry, n (%) | |
| Extended oligoarticular | 2 (10) |
| Polyarticular (RF negative) | 8 (40) |
| Polyarticular (RF positive) | 10 (50) |
| Systemic | 0 |
| Prior biologic therapy, n (%) | 4 (20) |
| Tocilizumab | 3 (15) |
| Anti-TNF therapy | 4 (20) |
| Adalimumab | 4 (20) |
| Etanercept | 1 (5) |
| Concomitant MTX therapy at Day 1, n (%) | 16 (80) |
| MTX dose, mg/m2/week | 8.9 (6.0–10.3) |